AstraZeneca (AZN) and FibroGen Inc. (FGEN) Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Diseas

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to AstraZeneca (AZN) and FibroGen Inc. (FGEN) Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Diseas
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 2,394,190       

(NASDAQ: FGEN) Delayed: 9.71 --0 (-0%)
Previous Close $9.71    52 Week High $31.90 
Open $9.71    52 Week Low $14.38 
Day High $9.71    P/E N/A 
Day Low $9.71    EPS $0.00 
Volume 745,000